Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,800

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2030

Conditions
Human Papillomavirus (HPV) InfectionHPV (Human Papillomavirus)-Associated Carcinoma
Interventions
BIOLOGICAL

2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

Two doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0 and 6 months.

BIOLOGICAL

3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

Three doses of the experimental vaccine were injected into the deltoid muscle of the upper arm according to the immunization schedule at 0, 2, and 6 months.

All Listed Sponsors
collaborator

Chengdu Institute of Biological Products Co.,Ltd.

INDUSTRY

lead

National Vaccine and Serum Institute, China

INDUSTRY

NCT06632912 - Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging | Biotech Hunter | Biotech Hunter